GTHX | G1 Therapeutics, Inc.
Quick infos Headquarters: North Carolina, United States Trade prices Volume: Market Cap: 220.79M Prev closed: Open: 8.96 High: 9.22 Low: 8.73 52 week low: 8.04 52 week high: 26.69 Dividends: No Dividends Next ER: August 3, 2022 Before Market Opens
Company Profile Our mission is to discover, develop and deliver innovative therapies that improve the lives of those affected by cancer.
Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing two novel therapies for people living with cancer.
Earnings History Date EPS / Forecast Revenue / Forecast November 9, 2022 August 3, 2022 -0.92 / -1.0210.57M / 9.09MBeat! May 4, 2022 -1.15 / -0.97986.9M / 6.37MBeat! February 23, 2022 -0.94 / -1.035.8M / 5.71MBeat! November 3, 2021 -1 / -1.024.86M / 4.78MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 3, 2022 8.70 8.86 9.17
7.83
2.43M 4.69% Aug 2, 2022 8.31 8.03 8.45
8.03
540.73K 2.21% Aug 1, 2022 8.13 8.25 8.71
7.98
1.14M -2.4% Jul 29, 2022 8.33 8.25 8.36
8.00
466.13K 0.24% Jul 28, 2022 8.31 8.17 8.31
7.82
498.24K 0.85% Jul 27, 2022 8.24 8.35 8.47
7.95
652.95K 0.61% Jul 26, 2022 8.19 8.10 8.77
7.88
1.21M -0.12% Jul 25, 2022 8.20 8.19 8.36
8.06
466.09K 0.12% Jul 22, 2022 8.19 8.51 8.62
7.96
573.45K -3.76% Jul 21, 2022 8.51 8.12 8.52
8.07
629.49K 4.55% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:2008 Employees:104 News
G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference finance.yahoo.com Mar 8, 2022 11:15 am
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates finance.yahoo.com Mar 8, 2022 7:45 am
Are Institutions Heavily Invested In G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shares? finance.yahoo.com Mar 7, 2022 10:58 am G1 Therapeutics reports inducement grants seekingalpha.com Mar 2, 2022 6:49 am G1 Therapeutics GAAP EPS of -$0.94 beats by $0.09, revenue of $5.79M beats by $0.07M seekingalpha.com Feb 23, 2022 7:34 pm G1 Therapeutics Q4 2021 Earnings Preview seekingalpha.com Feb 23, 2022 12:24 am 'Mad Money' Lightning Round: Peloton, G1 Therapeutics thestreet.com Nov 4, 2021 4:00 am G1 Therapeutics, Inc (GTHX) Q3 2021 Earnings Call Transcript fool.com Nov 3, 2021 4:01 pm
G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022 finance.yahoo.com Feb 9, 2022 9:15 am
Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet? finance.yahoo.com Jan 5, 2022 5:06 am
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Jan 3, 2022 5:30 pm G1 Therapeutics ends co-promotion pact with Boehringer Ingelheim; expands sales force seekingalpha.com Dec 16, 2021 8:06 pm
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Dec 1, 2021 6:20 pm
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), TrodelvyĀ® (Sacituzumab Govitecan-Hziy) finance.yahoo.com Nov 29, 2021 7:00 am
G1 Therapeutics to Participate in Two Upcoming Conferences finance.yahoo.com Nov 10, 2021 11:40 am
Recap: G1 Therapeutics Q3 Earnings finance.yahoo.com Nov 4, 2021 4:31 pm
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights finance.yahoo.com Nov 4, 2021 4:01 pm
G1 Therapeutics, Inc. to Host Earnings Call finance.yahoo.com Nov 4, 2021 2:45 pm
G1 Therapeutics, Inc. to Host Earnings Call finance.yahoo.com Nov 4, 2021 2:30 pm
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer finance.yahoo.com Nov 4, 2021 9:02 am This company doesn't provide a dividend.
Key Persons Chief Medical Officer : Raj Malik Talk about G1 Therapeutics, Inc. below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
investor.g1therapeutics.com If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.